http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 18:47:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html si-local-file:///var/storage/secattach/20260807/26892447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html Fri, 07 Aug 2026 18:47:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html si-local-file:///var/storage/secattach/20260807/26892447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html Fri, 07 Aug 2026 18:47:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html si-local-file:///var/storage/secattach/20260807/26892446.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html Fri, 07 Aug 2026 18:46:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html si-local-file:///var/storage/secattach/20260807/26892446.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html Fri, 07 Aug 2026 18:46:00 -0400 AMGN O.00027089 http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html si-local-file:///var/storage/secattach/20260806/26885473.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html Thu, 06 Aug 2026 17:10:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html si-local-file:///var/storage/secattach/20260806/26885473.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html Thu, 06 Aug 2026 17:10:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html si-local-file:///var/storage/secattach/20260806/26882994.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html Thu, 06 Aug 2026 15:17:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html si-local-file:///var/storage/secattach/20260806/26882994.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html Thu, 06 Aug 2026 15:17:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html si-local-file:///var/storage/secattach/20260806/26882608.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html Thu, 06 Aug 2026 14:13:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html si-local-file:///var/storage/secattach/20260806/26882608.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html Thu, 06 Aug 2026 14:13:00 -0400 AMGN O.00027089 http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24345+at+Bernstein+SocGen+Group/26880633.html Bernstein SocGen Group analyst Courtney Breen raised the price target on Amgen (NASDAQ: AMGN) to $345.00 (from $335.00) while maintaining a Market Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24345+at+Bernstein+SocGen+Group/26880633.html Thu, 06 Aug 2026 09:24:43 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html (Updated - August 5, 2026 9:53 AM EDT) <p>TD Cowen analyst Yaron Werber raised the price target on Amgen (NASDAQ: AMGN) to $452.00 (from $420.00) while maintaining a Buy rating.</p><p>The analyst commented: "Big Beats, Raised Guidance, And Key Ph3 Catalysts Ahead; Q2 beat-and-raise with revs/EPS $10.1B/$6.29 vs cons $9.4B/$5.60. FY26 revs/EPS guidance raised. Beats across growth & existing franchises show pipeline is offsetting LOEs and pricing pressure. Ph3 data for dazo in SjD, NVS/IONS Lp(a)HORIZON (H2:26), Teze EoE (Q4:26), MariTide in obesity (H1:27) support attractive setup into FY27. We raise PT to $452 (+$32), 18x FY27E EPS. Reiterate Buy."</p> http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html Wed, 05 Aug 2026 09:53:23 -0400 AMGN http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html (Updated - August 5, 2026 9:53 AM EDT) <p>TD Cowen analyst Yaron Werber raised the price target on Amgen (NASDAQ: AMGN) to $452.00 (from $420.00) while maintaining a Buy rating.</p><p>The analyst commented: "Big Beats, Raised Guidance, And Key Ph3 Catalysts Ahead; Q2 beat-and-raise with revs/EPS $10.1B/$6.29 vs cons $9.4B/$5.60. FY26 revs/EPS guidance raised. Beats across growth & existing franchises show pipeline is offsetting LOEs and pricing pressure. Ph3 data for dazo in SjD, NVS/IONS Lp(a)HORIZON (H2:26), Teze EoE (Q4:26), MariTide in obesity (H1:27) support attractive setup into FY27. We raise PT to $452 (+$32), 18x FY27E EPS. Reiterate Buy."</p> http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html Wed, 05 Aug 2026 09:53:23 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html (Updated - August 5, 2026 9:18 AM EDT) <p>RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $370.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Impressive Q For A Stock That Has Clear Momentum And Relatively Quiet Rest Of 2026; Quarter was a meaningful beat ($9.54b top-line vs $9.43b consensus) primarily driver by Repatha ($953m vs $921m consensus as uptake in high-risk primary prevention continues to gain momentum), Evenity ($714m vs $642m consensus and +38% Y/Y), Tepezza ($576m vs $544m consensus and 14% Y/Y) and Uplizna ($335m vs $222m consensus driven by uptake across http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html Wed, 05 Aug 2026 09:18:50 -0400 AMGN http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html (Updated - August 5, 2026 9:18 AM EDT) <p>RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $370.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Impressive Q For A Stock That Has Clear Momentum And Relatively Quiet Rest Of 2026; Quarter was a meaningful beat ($9.54b top-line vs $9.43b consensus) primarily driver by Repatha ($953m vs $921m consensus as uptake in high-risk primary prevention continues to gain momentum), Evenity ($714m vs $642m consensus and +38% Y/Y), Tepezza ($576m vs $544m consensus and 14% Y/Y) and Uplizna ($335m vs $222m consensus driven by uptake across http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html Wed, 05 Aug 2026 09:18:50 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24440+at+UBS/26871033.html UBS analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $440.00 (from $420.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24440+at+UBS/26871033.html Wed, 05 Aug 2026 08:54:35 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+Wells+Fargo/26870465.html Wells Fargo analyst Mohit Bansal raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $390.00) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+Wells+Fargo/26870465.html Wed, 05 Aug 2026 07:56:04 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24450+at+BMO+Capital/26870188.html BMO Capital analyst Evan David Seigerman raised the price target on Amgen (NASDAQ: AMGN) to $450.00 (from $400.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24450+at+BMO+Capital/26870188.html Wed, 05 Aug 2026 07:11:00 -0400 AMGN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AMGEN+INC+++++++++++++++++For%3A+Jun+30/26869288.html si-local-file:///var/storage/secattach/20260805/26869288.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AMGEN+INC+++++++++++++++++For%3A+Jun+30/26869288.html Wed, 05 Aug 2026 06:02:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AMGEN+INC+++++++++++++++++For%3A+Jun+30/26869288.html si-local-file:///var/storage/secattach/20260805/26869288.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++AMGEN+INC+++++++++++++++++For%3A+Jun+30/26869288.html Wed, 05 Aug 2026 06:02:00 -0400 AMGN O.00027089